Dr. Gabriel Ueda

Pathologist · Institut Curie · France (FR) · Oncology

Tier 1STK-0053GoodOwner MSL RARachel Adeyemi

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: SCLC, NSCLC
Scientific interests: PD-L1 biomarkersImmunotherapy sequencingElderly patients
Engagement preference: In person
Advisory boards: 4
Publications: 205
Source system: Manual
Data quality: Good

Engagement plan

Cadence target for Tier 1: 4 per year (assumption)

Last engaged: 30 Jul 2026 (47 days ago)
Next planned contact: 29 Oct 2026
Last 6 months vs target: 100%
3 of 2 expected engagements

Insights from this stakeholder (1)

INS-0038PD-L1 testing turnaround
19 Mar 2026 · Efficacy
MediumArchived

Engagement history (3)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
30 Jul 2026	Medical education	Phone	Rachel Adeyemi	Vantrexa	PD-L1 testing turnaround	0	—	Reviewed	ENG-0097
26 May 2026	Scientific exchange	Phone	Rachel Adeyemi	Vantrexa	Elderly / ECOG 2 patients	0	—	Reviewed	ENG-0118
17 Mar 2026	Congress meeting	Phone	Rachel Adeyemi	Vantrexa	PD-L1 testing turnaroundComparator checkpoint monotherapy+1	1	MI request	Reviewed	ENG-0006

Timeline

30 Jul 2026
Medical education
PD-L1 testing turnaround
26 May 2026
Scientific exchange
Elderly / ECOG 2 patients
17 Mar 2026
Congress meeting
PD-L1 testing turnaround, Comparator checkpoint monotherapy, Sequencing after progression

Related stakeholders (3)

Institut Curie

Dr. Noor Yamamoto
Academic nephrologist
Tier 1
Dr. Quentin Quinn
Academic nephrologist
Tier 1
Dr. Liam Quinn
Academic nephrologist
Tier 3